Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation. Dr. Brahmer is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).

Josephine (Joy) Feliciano, M.D., is an assistant professor of oncology at The Johns Hopkins University School of Medicine and a faculty member of the Johns Hopkins Kimmel Cancer Center. She serves as medical director of the Thoracic Oncology Program at Johns Hopkins Bayview Medical Center, as well as co-director of the outpatient oncology clinic at Johns Hopkins Bayview. Dr. Feliciano completed both undergraduate and postgraduate medical training at Georgetown University, as well as residency training, where she was selected as chief resident. She spent three years at Northwestern completing clinical training in hematology and oncology, then joined the faculty at University of Maryland Greenberg Cancer Center. At the University of Maryland, Feliciano focused on lung cancer screening and health disparities research for patients with lung cancer. While there, she also earned a certificate degree in the Epidemiology and Human Genetics Program for Clinical Investigation. Dr. Feliciano is also a member of the Miller Coulson Academy of Clinical Excellence. She also serves as the inaugural Medical Director of the Sidney Kimmel Cancer Diagnostic and Treatment Planning Center. Dr. Feliciano is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Gastroesophageal Junction Cancer.

Dr. Kristen Marrone is a thoracic medical oncology specialist in Baltimore, caring for patients with lung cancer and esophageal cancer. She is the Program Director of the Hematology/Medical Oncology Fellowship Program at the Johns Hopkins School of Medicine. Dr. Marrone received her undergraduate degree in psychology with a neuroscience concentration from Pennsylvania State University. She earned her M.D. from Drexel University College of Medicine. She completed her residency at Yale-New Haven Hospital and performed a fellowship in medical oncology at Johns Hopkins University School of Medicine. Dr. Marrone joined the Johns Hopkins faculty in 2017. Her research interests include clinical trial development and translational studies focusing on optimization of immunotherapy in oncogene driven non-small cell lung cancer. Dr. Marrone is a member of the American Association of Cancer Research, the American Society of Clinical Oncology, the International Association for Study of Lung Cancer and the Society for Immunotherapy in Cancer. Dr. Marrone is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Squamous Cell Lung Carcinoma.

Taofeek Owonikoko is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Owonikoko is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Owonikoko is currently accepting new patients.

Patrick Forde is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Forde is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, Small Cell Lung Cancer (SCLC), and Bone Marrow Transplant. Dr. Forde is currently accepting new patients.

Richard Battafarano, M.D., Ph.D., joins the Johns Hopkins Department of Surgery as director of the Division of General Thoracic Surgery and the first regional director of general thoracic surgery. He comes to Johns Hopkins from University of Maryland Medical System, where he was chief of the Division of Thoracic Surgery. Dr. Battafarano specializes in the treatment of benign and malignant diseases and lesions of the chest, including minimally invasive operations such as video-assisted thoracscopic surgery (VATS) for lung and esophageal cancers. He also has a special interest in treating Barretts esophagus, emphysema, mesothelioma and paraesophageal hernias. The focus of Dr. Battafaranos basic and translational research includes outcomes in the surgical management of early stage lung cancer patients with neuroendocrine histology, optimal management of lung cancer patients with mediastinal lymph node metastases, and the effect of survivin overexpression in the development of esophageal cancer. Dr. Battafarano sees patients at The Johns Hopkins Hospital and the Johns Hopkins Health Care & Surgery Centers at Green Spring Station and at White Marsh. Dr. Battafarano is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Thymic Epithelial Tumor, Pleuropulmonary Blastoma, Gastrectomy, and Endoscopy.

Malcolm V. Brock, M.D., a graduate of the Johns Hopkins University School of Medicine, the Johns Hopkins general surgical residency program and the Johns Hopkins fellowship in cardiothoracic surgery, is a specialist in thoracic oncology, and is a Professor of Surgery and Oncology at the Johns Hopkins University School of Medicine. In additional to clinical thoracic oncology, his clinical interests include surgery for palmar, axillary and pedal hyperhidrosis. Dr. Brock is a surgeon who conducts cancer research at the Johns Hopkins Kimmel Cancer Center, specializing in applying innovative basic science research to patient care. His main research interests are in developing novel molecular biomarkers for solid tumors that can help clinicians diagnose cancer earlier and treat it more effectively. He has studied using DNA-based methods to predict which patients will develop recurrent lung cancer, even after successful surgery, and to predict patients with esophageal cancer who will be sensitive to certain chemotherapy. Dr. Brock has published over 70 original research papers, book chapters and review articles, and has presented often at national and international conferences. He has been the recipient of research funding from the National Institutes of Health (NIH), the Thoracic Surgery Foundation for Research Excellence, the American College of Surgery Oncology Group and the Society of Surgical Oncology. Dr. Brock is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Esophageal Cancer, Non-Small Cell Lung Cancer (NSCLC), Tissue Biopsy, and Endoscopy.

Dr. Stephen C. Yang is a professor of surgery and medical oncology at Johns Hopkins University School of Medicine and The Johns Hopkins Hospital. In October 2008 he was named the first recipient of The Arthur B. and Patricia B. Modell Professor in Thoracic Surgery. Dr. Yang is an extreme supporter of medical students, being the only surgeon (amongst 20 chosen from the School of Medicine) for the medical student advisory Colleges system, and is the faculty sponsor for the Surgery Interest Group and the Asian Pacific American Medical Student Association. Dr. Yang graduated from Duke University with a B.A. in Chemistry and received his M.D. degree from the Medical College of Virginia. He completed his general surgery residency at the University of Texas Health Science Center at Houston, and finished his cardiothoracic surgery fellowship at the Medical College of Virginia. He also completed a 3 year thoracic surgical oncology research fellowship at the University of Texas M. D. Anderson Cancer Center. He currently serves on the Postgraduate Affairs, Medical School Admissions, Educational Policy, and Curriculum Reform Committees in the Johns Hopkins School of Medicine. He served on numerous national and international committees for these organizations, and is the Taskforce Chair on the Looking to the Future Residency Scholarships for the Society of Thoracic Surgeons He is Editor of Practical Reviews in Chest Medicine and guest editor/ reviewer for numerous peer review journals. He is co-editor of the book Current Therapy in Thoracic and Cardiovascular Surgery, edited the esophageal surgical section in the 2nd edition of Atlas of Gastrointestinal Surgery with John Cameron, M.D., and series editor-in-chief of The Early Diagnosis of Cancer also editing the book volume of The Early Diagnosis of Lung Cancer. In 2001, he and his lung transplant team were featured in the ABC series 24/7 and is currently also being followed in the sequel to that series focusing in on resident and medical student teaching. This series as well as other experiences are still shown on the Discovery Channel. The extensive work in preparing an esophageal cancer patient for surgery on the BBC and the Discovery Channel. Dr. Yang's laboratory research interests include using molecular techniques for lung cancer screening and for molecular staging of micrometastasis to predict recurrence following surgical resection. His clinical practice and research covers the breath of general thoracic surgery in pulmonary and esophageal surgery, video-assisted and robotics thoracic surgery, mediastinal and pleural work, lung volume reduction surgery for emphysema, and work in geriatric thoracic surgery. Dr. Yang is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, Endoscopy, and Thymectomy.

Dr. Anagnostou is an Associate Professor of Oncology, co-director of the Upper Aerodigestive Malignancies Program, director of the Thoracic Oncology Biorepository, leader of Precision Oncology Analytics and co-leader of the Molecular Tumor Board and the Thoracic Oncology Precision Medicine Center of Excellence in the Sidney Kimmel Cancer Center at Johns Hopkins. She has established the Molecular Oncology laboratory that seeks to understand the genomic wiring of response and resistance to immunotherapy through integrative genomic, transcriptomic, single-cell and liquid biopsy analyses of tumor and immune evolution. Dr. Anagnostou graduated from Medical School of the National and Kapodistrian University of Athens, Greece and received a PhD from the same institution. After completing her internal medicine residency at Yale-New Haven Hospital, she subsequently trained in Medical Oncology at Johns Hopkins. Dr. Anagnostou is a translational cancer investigator, focusing on large-scale genomic and liquid biopsy analyses in human cancers. Her group has discovered novel genomic mechanisms of response and resistance to immunotherapy and her research is particularly focused on understanding the molecular mechanisms of response and resistance to these therapies, capturing these by minimally invasive methods and translating this knowledge into novel technologies and innovative therapeutic approaches for cancer patients. She is the international study chair of the first ctDNA-based molecular response adaptive immuno-chemotherapy clinical trial for metastatic non-small cell lung cancer (NCT04093167). Dr. Anagnostou's long term goal is to transform medical oncology to personalized molecular oncology, where treatment decisions are tailored to cancer genomics and molecular real-time response assessments informed by liquid biopsies. Dr. Anagnostou is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, and Gastroesophageal Junction Cancer.

Dr. K. Ranh Voong specializes in thoracic malignancies, including lung, esophageal, thymic cancers, and mesothelioma. She treats patients at both the Johns Hopkins Thoracic Center of Excellence at Johns Hopkins Bayview and at the Proton Center at Sibley Memorial Hospital. She has extensive expertise in proton therapy, SBRT, IMRT for tumors involving the chest. She is the Principal Investigator on grants from Lung Cancer Research Foundation and Hopkins-Wellspan. She is the Principal Investigator of a prospective study evaluating the immunogenic effects of SABR alone on systemic T cell response in patients with stage I NSCLC. She is the principal investigator of a multi-institutional prospective trial showing that routine review of patient-reported outcome measures informs radiation on-treatment toxicity burden assessment and care delivery. She was the Quality of Life Co-chair of a Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) For Malignant Pleural Mesothelioma (NRG-LU006). She has been invited to participate in national and regularly lectures on thoracic malignancies and protons for thoracic malignancies therapy. In her research, Dr. Voong is dedicated to improving the outcomes of patients with thoracic malignancies, by exploring avenues to better understand and optimize the delivery of radiotherapy. Dr. Voong is also the Program Director for the Radiation Oncology Residency Program. She mentors residents, medical students. Make A Gift. Dr. Voong is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Non-Small Cell Lung Cancer (NSCLC).

Russell Hales, M.D., is an assistant professor of radiation oncology and molecular radiation sciences at the Johns Hopkins University School of Medicine. He also is director of the thoracic multidisciplinary clinic. His research focuses on reconstructing health delivery models to enhance value and improve clinical outcomes. He also studies the effect of immunotherapy and RT in thoracic tumors. Dr. Hales was awarded an R21 grant to study the use of dynamic MRI in predicting tumor motion in patient with lung cancer. Taken together, his research focuses on optimizing patient outcomes using resources from physics, engineering, biology and health delivery systems. Dr. Hales’ efforts extend beyond radiation oncology and clinical management. He has helped to lead in the thoracic oncology program, which includes 20 faculty members and nearly 50 staff, to help chart a vision for this program’s future. In the last four years, the program has gradually transitioned from The Johns Hopkins Hospital campus to Johns Hopkins Bayview Medical Center. Dr. Hales was tasked to head the building and design committee that worked with architects to create a structure conducive to 21st century oncology care. His work extends beyond the bricks and mortar of the new cancer center today to team development within the thoracic oncology program. Simply put, the thoracic oncology move was designed to conceptualize the transition of care from department-based to disease-based medicine. As such, Dr. Hales has worked to integrate the efforts of specialists in medical oncology, thoracic surgery, interventional pulmonology, pathology and radiology. These experts share a clinical space focused on thoracic malignancies and bring a patient-centered model of care to their group. Dr. Hales graduated from Brigham Young University Summa Cum Laude and Valedictorian in 2001. He attended Johns Hopkins Medicine and graduated with an M.D. in 2005. He trained on the Osler Medical Service and attended residency at Johns Hopkins. He joined the faculty at Hopkins in 2010. Dr. Hales focus in program building, research and clinical endeavors is robust, but he understands the key role of academia in training future leaders in medicine. He has been awarded Teacher of the Year in the department of radiation oncology at Hopkins for three of the last six years. He is a well-respected lecturer and travels nationally to speak at conferences and educational workshops about novel therapies in lung and esophagus cancer. Make A Gift. Dr. Hales is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Thymic Epithelial Tumor, Non-Small Cell Lung Cancer (NSCLC), and Endoscopy.

Christine L Hann, completed her MD and Ph.D. at Jefferson Medical College/Thomas Jefferson University follwed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer. Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research. Specific research projects include: 1) Studying mechanisms of resistant to small molecule inhibitors of the antiapoptotic protein, BCL-2 using patient-derived xenograft models. Her preclinical work has led to an NCI-sponsored Phase 1/2 clinical trial combining a BCL-2 inhibitor with a TORC1/2 inhibitors which is currently underway (NCT03366103). 2) Preclinical evaluation of various therapeutics including epigenetic modulators (LSD1 inhibitors) and nanoliposome chemotherapy in SCLC PDXs; 3) Modeling and characterizing chemoradiotherapy resistance in preclinical models of SCLC. She, along with Dr. Luigi Marchionni in Biostatistics and Dr. Phuoc Tran in the Department of Radiation Oncology, were recently awarded a 5-year NCI-sponsored U01 grant to study mechanisms of chemoradiation resistance in SCLC. Dr. Hann is PI of several trials in SCLC and NSCLC and is leading investigator-initiated clinical trials in SCLC and NETs. Dr. Hann is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma.

Mark Katlic is a Thoracic Surgeon in Randallstown, Maryland. Dr. Katlic is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Endoscopy, and Thymectomy.

David Ettinger is an Oncologist in Lutherville, Maryland. Dr. Ettinger is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Thymic Epithelial Tumor.

Gavin Henry is a General Surgeon and a Thoracic Surgeon in Baltimore, Maryland. Dr. Henry is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, ALK-Positive Non-Small Cell Lung Cancer, Thymectomy, and Advanced Bronchoscopy.

Suman Rao is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Rao is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Squamous Cell Lung Carcinoma, and Small Cell Lung Cancer (SCLC). Dr. Rao is currently accepting new patients.

Dr. William H. Sharfman is an associate professor of oncology and dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous oncology, dermatology and immunotherapy. He helped create the well-established Melanoma Program at the Johns Hopkins Kimmel Cancer Center in 1994. Dr. Sharfman serves as the director of cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program. He earned his M.D. from the University of Toledo College of Medicine. He completed his residency at Cleveland Clinic and performed a fellowship in hematology and oncology at Cleveland Clinic. Dr. Sharfman's research interests include novel therapies for high risk and advanced melanoma patients. Dr. Sharfman is rated as an Experienced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Eccrine Porocarcinoma, and Familial Pancreatic Cancer.

Dr. Howard Steiner is an instructor of medicine at the Johns Hopkins School of Medicine. He has been practicing pulmonary and sleep consultative medicine since 1989. In his role as a diagnostician, he guides the evaluation and management of respiratory problems including infectious, malignant, allergic, autoimmune, and sleep-related disorders. He has been part-time faculty in the Johns Hopkins Pulmonary Division since 1991, is a Fellow in the American College of Chest Physicians, and mentors medical students, residents, and pulmonary fellows training at the Johns Hopkins Hospital. Contact for Research Inquiries 10755 Falls Road Pavilion I, Suite 200 Lutherville, MD 21093 Phone: (410) 583-7124 Selected Publications Lwebuga-Mukasa JS, Steiner H. Monoclonal antibody to rat lung Maclura Pomifera agglutinin (MPA) lectin binding glycoprotein localizes apically on rat and human type II pneumocytes and Clara cells. J Cell Biol 107:71a, 1989. Roberts PJ, McBean GJ, Steiner H, Kohler C, Schwarcz R. Lesioning Effects of Ibotenate in the immature rat brain and protection by 2-amino-7 phosphonoheptanoic acid. Soc Neurosci Abst 9:261, 1983. Steiner H, Ingbar DI. Mechanisms of lung injury and repair. In: Matthay RA, Matthay MA, Wiedemann HP eds. Annual Review of Pulmonary and Critical Care Medicine. Hanley & Belfus (Philadelphia, 1989), pp 205-223. Steiner H, Lwebuga-Mukasa JS. A549 cells display distinct functional and morphologic properties depending on their culture substratum. J Cell Biol 107:71a, 1989. Steiner H, Lwebuga-Mukasa JS. A549 cells produce a factor which is Mitogenic for human lung fibroblasts. Amer Rev Resp Dis 139:A492 1989. Steiner H, McBean GJ, Kohler C, Roberts PJ, Schwarcz R. Ibotenate Induced neuronal degeneration in immature rat brain. Brain Research 307:117-124, 1984. Dr. Steiner is rated as an Experienced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Bronchiectasis, Obstructive Sleep Apnea, Lung Metastases, and Interstitial Lung Disease.

Richard Schraeder is a Hematologist Oncology specialist and a Hematologist in Towson, Maryland. Dr. Schraeder is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Retroperitoneal Liposarcoma. Dr. Schraeder is currently accepting new patients.

Andrew Long is a Radiologist and an Interventional Radiologist in Randallstown, Maryland. Dr. Long is rated as an Experienced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Gallbladder Disease, SVC Obstruction, May Thurner Syndrome, Bone Marrow Aspiration, and Endoscopy.